Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an announcement.
CR Sanjiu has announced its unaudited preliminary financial results for the year ended December 31, 2024, showing a notable financial performance with a total operating revenue increase of 11.63% and an operating profit rise of 19.28% compared to the previous year. The announcements indicate a strong financial growth trajectory for CR Sanjiu, which may positively impact its positioning in the pharmaceutical industry. The increase in shareholder equity and basic earnings per share suggests improved returns for stakeholders.
More about China Resources Pharmaceutical Group Ltd.
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (CR Sanjiu) is a leading pharmaceutical company based in the People’s Republic of China and is listed on the Shenzhen Stock Exchange. It is a subsidiary of China Resources Pharmaceutical Group Limited, which holds a 63.02% indirect ownership. The company is involved in the medical and pharmaceutical industry.
YTD Price Performance: -6.62%
Average Trading Volume: 2,178
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €4.12B
Find detailed analytics on 3320 stock on TipRanks’ Stock Analysis page.